Back to results
US 2026/0273055 A1Published application
Utilizing t cells derived from tumor draining lymph nodes for chimeric antigen receptor (car) t cell therapy for the treatment of cancer
AssigneeCornell University
InventorJonathan Villena-Vargas
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions and methods for targeted treatment of cancer. The present disclosure provides CAR therapy comprising cells from a patient's tumor draining lymph node expressing a chimeric antigen receptor.
Claims35
A lymphocyte from a tumor-draining lymph node (TDLN) of a subject afflicted with a cancer, wherein the lymphocyte comprises a CAR polypeptide comprising:
- a) at least one intracytoplasmic signaling region comprising a cluster of differentiation 3 zeta (CD3ζ) domain, and
- b) an antigen binding domain specific for a cancer antigen.
Dependencies are inferred from the claim text.